contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


herantis-pharma-plc-financial-reporting-and-annual-general-meeting-in-2026

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096 is a small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein. HER-096 combines the mechanism of action of CDNF with subcutaneous administration. The Phase 1a clinical trial demonstrated a good safety and tolerability profile as well as blood-brain barrier penetration of subcutaneously administered HER-096. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.

Partnership Roche & Herantis Pharma might be a ”winning combo”…. https://x.com/ristopar/status/1998767454265422170?s=46

I asked Elon Musk Ai’s  opinion, is partnership Roche & Herantis Pharma potentiial and viable. Answer: First to Stop (or Cure) PD? Not Quite—But Game-Changers in the Works PD’s brutal—no cure, just symptom managers. “Stopping” progression is the holy grail for disease-modifiers, and both programs hype that potential, but neither’s there yet: • HER-096: Fresh off Phase 1b success (safe, brain-penetrant, stable symptoms), plus a clean 6-month tox study in Nov 2025. It’s positioned as a potential “first-in-class” to halt progression by hitting root causes, with full biomarkers due end-2025. Phase 2 efficacy readouts? Not till 2027-ish. Backed by MJFF and Parkinson’s UK, it’s promising but early. • Roche’s Prasinezumab: Further along in Phase III (starting late 2025/early 2026), with data showing motor slowdown in subsets. If it pans out, it could be the first approved modifier to slow PD—not cure, but a massive leap. Roche’s betting big, calling it a “revolution” in neurodegeneration. Neither’s a cure (reversing damage fully? Decades away, if ever). But prasinezumab might claim “first to slow” bragging rights sooner, while HER-096 could differentiate on repair. If they partnered, it’d be a powerhouse combo—synergistic mechanisms, shared trials?

Herantis’s Antti Vuolanto was at Life Science Night talking about his company.               Topics: 00:00 Herantis Pharma briefly 01:56 Parkinson’s Disease: High Unmet Need Driving Market Growth 07:29 HER-096 10:53 HER-096 Phase 1 Program 12:12 Partnering & Financing Goal 13:48 External Validation of HER-096 for Disease Modification in Parkinson’s 14:54 Q&A session

Tomorrow, Herantis will participate in Inderes’ company evening, which will include a company presentation and a Q&A session. Questions can be sent during the event in the chat or via the forum. Messages sent here by tomorrow morning will still be reached.

HER-096 development is built on 15 years of research and development work related to CDNF’s role in neurodegeneration both in the academia and in the industry.  This work has generated many important insights and data to help us understand how HER-096 works, and how cells and tissues respond to exposure to HER-096.                    Herantis Pharma              Herantis Pharma - How does HER-096 work in the body?    Innovative therapies for better lives

Note, latest timing info!  Herantis expects to report the Phase 1b biomarker data by mid-January 2026, in advance of the JP Morgan Healthcare Conference week in San Francisco, where the Company’s management will be available for meetings.  Herantis plans to initiate a Phase 2 clinical trial in 2026 to evaluate the efficacy, safety, and tolerability of HER-096 in people with Parkinson’s disease.

This link contains key information about an approved, commonly used medication for the “treatment” of Parkinson’s disease. Much seems to be based on guesswork regarding the mechanism of action and contraindications. Hopefully, Herantis Pharma’s HER-096 gets on the fast track.            organon.com              sinemet_pi.pdf

Herantis Pharma

Herantis Pharma Plc – Company Release – December 11 2025, at 14.15 EET.Herantis Pharma Plc Financial Reporting and Annual General Meeting in 2026In 2026 Herantis Pharma Plc will publish its ...

Herantis Pharma Plc – Company Release – December 11 2025, at 14.15 EET.Herantis Pharma Plc Financial Reporting and Annual General Meeting in 2026In 2026 Herantis Pharma Plc will publish its financial reports as follows<table><tbody><tr><td>Report</td><td align="right">Release date</td></tr><tr><td>Financial Statements Release 2025</td><td align="right">5.3.2026</td></tr><tr><td>Annual Report for 2025</td><td align="right">30.3.2026</td></tr><tr><td>H1/2026 Half-a year report January-June</td><td align="right">20.8.2026</td></tr></tbody></table>Annual General Meeting 2026Herantis Pharma’s Annual General Meeting is scheduled for 23 April 2026. The Board of Directors will convene the meeting at a later date. The deadline for submission of proposals for the Annual General Meeting is 5 March 2026.The company's financial reviews are published in both Finnish and English through company releases and can be accessed on the company's website at <a href="https://herantis.com/investors/releases/">https://herantis.com/investors/releases/</a>.Herantis Pharma Plc observes a 30-day silent period prior to the publication of its financial statements and interim reports, during which the company does not comment on its financial position or outlook, nor meets with representatives of the capital markets or financial media.Herantis Pharma’s financial reporting calendar, silent periods, and the deadline for submitting proposals to the Annual General Meeting can also be found on our website at <a href="https://herantis.com/investors/calendar/">https://herantis.com/investors/calendar/</a>.Further informationTone Kvåle, CFOTel: +47 915 19576E-mail:&nbsp;<a href="mailto:ir@herantis.com">ir@herantis.com</a>Certified AdvisorUB Corporate Finance OyTel: +358 9 25 380 225E-mail:&nbsp;<a href="mailto:ubcf@unitedbankers.fi">ubcf@unitedbankers.fi</a>Herantis Pharma Plc is a clinical-stage biotechnology company developing disease-modifying therapies for Parkinson's disease. The Company's lead product, HER-096, is a first-in-class small peptide that combines the neuroprotective mechanism of cerebral dopamine neurotrophic factor (CDNF), with the convenience of subcutaneous administration. In a Phase 1b clinical trial, HER 096 was shown to be generally safe and well tolerated in Parkinson's disease patients. Herantis plans to advance HER-096 into a Phase 2 clinical trial in 2026 to evaluate efficacy, safety and tolerability in early-stage Parkinson's patients.Herantis is listed on the Nasdaq First North Growth Market Finland. <a href="http://www.herantis.com">www.herantis.com</a>

Report	Release date
Financial Statements Release 2025	5.3.2026
Annual Report for 2025	30.3.2026
H1/2026 Half-a year report January-June	20.8.2026